Category Archives: Other

Guangdong Seeks Public Input on Drug Procurement Plan for Diclofenac and Other Medicines

Guangdong Province’s Drug Exchange Center has released a draft procurement plan for diclofenac and other medicines, seeking public feedback to refine the process. The move aligns with the provincial healthcare bureau’s guidelines to ensure efficient and transparent drug procurement.

Policy Breakdown

  • Consultation Period: The public consultation runs from May 24 to June 4, 2025, providing stakeholders with ample time to review and submit feedback.
  • Feedback Mechanism: Interested parties are required to submit their opinions via email, including both scanned and electronic versions of the feedback form.
  • Contact Channels: The center offers online customer service and telephone support for inquiries, ensuring smooth communication.

Market Implications
The consultation process is expected to enhance the transparency and fairness of drug procurement, potentially reducing costs and improving supply chain efficiency. Analysts at Guangdong Healthcare Market Research suggest that this could lead to a 10–15% reduction in procurement costs for participating enterprises.

Industry Impact
Pharmaceutical companies are encouraged to actively participate in the consultation to shape procurement policies that align with industry needs. The move underscores Guangdong’s commitment to balancing regulatory rigor with market accessibility.

Looking Ahead
Stakeholders should monitor how the final procurement plan impacts market dynamics and competitive behavior. The long-term goal is to create a more conducive environment for the pharmaceutical industry’s high-quality development.

For detailed implementation plans and progress updates, refer to the official announcements from Guangdong’s Drug Exchange Center.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1926221856625397760

Policy Analysis & Guidance: Shanghai Suspends Procurement Qualification for Non-Compliant Drugs

Shanghai’s Centralized Medicine Bidding and Procurement Office announced on April 15 the suspension of procurement qualifications for certain drugs due to non-compliance with pricing regulations. The action targets Difenidol Hydrochloride Tablets produced by Renhetang Pharmaceutical Co., Ltd., effective from April 15, 2025, at 24:00.

Policy Breakdown and Market Implications

  • Non-Compliance Identified: The suspension stems from the producer’s failure to adjust prices in line with national medical insurance bureau requirements.
  • Product Details: The affected product is Difenidol Hydrochloride Tablets (25mg*12 tablets/board, aluminum-plastic packaging).
  • Regulatory Basis: The move aligns with national healthcare security policies aimed at ensuring drug pricing transparency and compliance.

Industry Impact
This action serves as a clear warning to pharmaceutical companies on the importance of adhering to pricing guidelines. Manufacturers are urged to review and adjust their pricing strategies to avoid procurement disruptions.

Looking Ahead
Stakeholders should monitor how such enforcement actions influence market dynamics and pricing strategies among pharmaceutical firms. The long-term goal is to foster a fair and regulated procurement environment.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2025/04/15/16814.shtml

Policy Analysis & Guidance: Guangdong’s Medical Supply Price Disclosure and Procurement Expansion

Guangdong Province’s Drug Exchange Center has completed the price disclosure process for medical consumables submitted by enterprises before April 1, 2025. Products not receiving objections during the publicity period have been officially published and incorporated into the negotiated procurement framework. This move underscores Guangdong’s commitment to enhancing price transparency and efficiency in medical supply procurement.

Policy Breakdown

  • Price Confirmation: Enterprises confirmed pricing information through the provincial platform’s “New Negotiating Price Listing (Automatic Confirmation Project)” module.
  • Public Disclosure: Products without objections during the publicity period are now available for negotiated procurement at or below listed prices.
  • Follow-Up Actions: Products requiring information verification or with pending registration statuses will be listed after resolution.

Market Implications
The initiative is expected to streamline interactions between medical consumable suppliers and healthcare institutions, potentially accelerating market entry by 10–15%. Analysts at Guangdong Healthcare Market Research highlight improved price transparency as a key driver for reducing procurement costs.

Industry Impact
Medical consumable manufacturers are encouraged to align with Guangdong’s pricing and procurement frameworks to maintain market access. The policy emphasizes procedural integrity, reducing administrative burdens post-approval.

Looking Ahead
Stakeholders should monitor future pricing adjustments and supply list updates to stay informed of changes impacting market dynamics and procurement strategies.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1911060639980195840